Toxicity to various agents – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Toxicity to various agents – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Methoxsalen for Treating Immune-Related Side Effects in Patients After Immunotherapy https://clinicaltrials.eu/trial/study-on-methoxsalen-for-treating-immune-related-side-effects-in-patients-after-immunotherapy/ Wed, 29 Apr 2026 15:01:05 +0000 https://clinicaltrials.eu/trial/study-on-methoxsalen-for-treating-immune-related-side-effects-in-patients-after-immunotherapy/ This clinical trial is focused on studying the treatment of immune-related adverse events that occur after receiving immunotherapy. These adverse events can include conditions such as colitis, pneumonitis, hepatitis, and dermatitis, which are side effects that some patients experience after their immune system is activated by cancer treatments known as immune checkpoint inhibitors. The treatment being tested in this study is called extracorporeal photopheresis (ECP), which involves a process where blood is treated outside the body to help manage these side effects. The medication used in this process is called methoxsalen, marketed under the name UVADEX.

The purpose of the study is to determine the safety and effectiveness of ECP in treating these immune-related side effects. Participants in the study will receive ECP treatment and will be monitored over a period of time to see how well the treatment works and to check for any side effects. The study will also look at how quickly patients respond to the treatment and how long the benefits last. The study aims to provide valuable information on whether ECP can be a safe and effective option for managing these challenging side effects of immunotherapy.

Throughout the study, participants will undergo regular assessments to track their progress and any changes in their condition. The study will help researchers understand the potential of ECP as a treatment option for patients who experience these immune-related side effects, offering hope for better management of these conditions in the future.

]]>